| Richard Stewart Robertson Hargrove, | |
|
1900 Electric Rd, Salem, VA 24153-7474 | |
| (540) 776-4000 | |
| Not Available |
| Full Name | Richard Stewart Robertson Hargrove |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Location | 1900 Electric Rd, Salem, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124587324 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 0102207324 (Virginia) | Primary |
| Entity Name | Lake Spring Physician Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568954287 PECOS PAC ID: 1254689482 Enrollment ID: O20180806000449 |
News Archive
Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).
An international team of scientists from Nanyang Technological University, Singapore (NTU Singapore), Brown University and the Massachusetts Institute of Technology (MIT) has developed an artificial intelligence (AI) platform that could one day be used in a system to assess vascular diseases, which are characterised by the abnormal condition of blood vessels.
During IVF treatment you will need to take certain drugs. For example, for IVF it will be Follicle Stimulating Hormones (FSH) which are used to stimulate the ovaries to produce a mature egg so that they can be fertilised externally and then put back into the womb.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
A new manifesto created by LGBT+ youth groups and sociolinguistics experts at the University of Nottingham has been launched to call for a more inclusive society in the UK.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Stewart Robertson Hargrove, 16637 Mlc Ln, Rockville, VA 23146-1855 Ph: (804) 514-2257 | Richard Stewart Robertson Hargrove, 1900 Electric Rd, Salem, VA 24153-7474 Ph: (540) 776-4000 |
News Archive
Vital Therapies, Inc., (VTI) is pleased to announce that the first two subjects have been enrolled at King's College Hospital in London in the expansion of its SILVER (Stabilization In LiVER failure) clinical trial in Europe. The trial is evaluating whether VTI's biological cellular therapy product, ELAD®, can prevent deterioration of liver function and improve the survival of patients with acute-on-chronic liver failure (ACLF).
An international team of scientists from Nanyang Technological University, Singapore (NTU Singapore), Brown University and the Massachusetts Institute of Technology (MIT) has developed an artificial intelligence (AI) platform that could one day be used in a system to assess vascular diseases, which are characterised by the abnormal condition of blood vessels.
During IVF treatment you will need to take certain drugs. For example, for IVF it will be Follicle Stimulating Hormones (FSH) which are used to stimulate the ovaries to produce a mature egg so that they can be fertilised externally and then put back into the womb.
RegeneRx Biopharmaceuticals, Inc. announced today that the first patient has been screened and is being enrolled in a Phase 2 clinical trial testing the Company's drug candidate RGN-259 in patients with dry eye associated with graft vs. host disease. The double-blind, placebo-controlled, investigator-sponsored trial is expected to enroll a total of 20 patients over the next several months, with data reported later in 2011. RGN-259 is a sterile, preservative-free topical eye drop formulation of the novel therapeutic peptide Thymosin beta 4, or Tβ4.
A new manifesto created by LGBT+ youth groups and sociolinguistics experts at the University of Nottingham has been launched to call for a more inclusive society in the UK.
› Verified 1 days ago
John Weidner Knarr, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2155 Apperson Dr, Salem, VA 24153 Phone: 540-444-2010 Fax: 540-444-2019 | |
Jeffrey Blake Lipscomb, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1970 Roanoke Blvd, Salem, VA 24153 Phone: 540-982-2463 Fax: 540-983-1011 | |
Dr. Andrew Maiolo, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1802 Braeburn Dr, Salem, VA 24153 Phone: 540-772-3430 Fax: 540-776-2051 | |
Dr. Charles John Schleupner, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1970 Roanoke Boulevard, Salem, VA 24153 Phone: 540-982-2463 Fax: 540-855-3406 | |
Dr. Paul D Richards, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Electric Rd, Salem, VA 24153 Phone: 540-774-8660 Fax: 540-774-9195 | |
Dr. Jane E Lindsay, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 1900 Electric Rd, Salem, VA 24153 Phone: 540-728-0332 | |
Richard Prokopchak, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2850 Keagy Rd, Salem, VA 24153 Phone: 540-375-9375 Fax: 540-375-9376 |